Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2

Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mR...

Full description

Saved in:
Bibliographic Details
Published inBMC medicine Vol. 20; no. 1; pp. 32 - 7
Main Authors Ukey, Rahul, Bruiners, Natalie, Mishra, Hridesh, Mishra, Pankaj K., McCloskey, Deborah, Onyuka, Alberta, Chen, Fei, Pinter, Abraham, Weiskopf, Daniela, Sette, Alessandro, Roy, Jason, Gaur, Sunanda, Gennaro, Maria Laura
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 25.01.2022
BioMed Central
BMC
Subjects
Ad26.COV2.S
Ad26COVS1
Analysis
Antibodies
Antibodies, Viral
Antibody binding
Antigen-antibody reactions
Antigen-specific B cells
Antigens
BNT162b2
Cell culture
Correspondence
COVID-19
COVID-19 Vaccines
Durability
FDA approval
Hospital care
Humans
Immunity, Humoral
Immunization
Immunogenicity
Immunology
Infections
Laboratories
Lymphocytes
Lymphocytes T
mRNA
mRNA Vaccines
mRNA-1273
Neutralizing antibodies
Pandemics
Peptides
Plasma
Prevention
Proteins
Public health
Regression analysis
RNA, Messenger - genetics
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Software
Testing
Vaccination
Vaccines
Viral diseases
Viral infections
United States
United States > US
BNT162b2
Neutralizing antibodies
Ad26.COV2.S
mRNA-1273
Antigen-specific B cells
Antibody binding
Antigen-specific T cells
Online AccessGet full text

Cover

Abstract Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
AbstractList Background Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. Main body We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. Conclusions A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient. Keywords: Ad26.COV2.S, BNT162b2, mRNA-1273, Antibody binding, Neutralizing antibodies, Antigen-specific B cells, Antigen-specific T cells
Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines.BACKGROUNDProtection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines.We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups.MAIN BODYWe investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups.A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.CONCLUSIONSA dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
Background Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. Main body We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. Conclusions A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
Abstract Background Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. Main body We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. Conclusions A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
ArticleNumber 32
Audience Academic
Author Chen, Fei
Bruiners, Natalie
Mishra, Pankaj K.
Weiskopf, Daniela
Onyuka, Alberta
Roy, Jason
Sette, Alessandro
Mishra, Hridesh
McCloskey, Deborah
Pinter, Abraham
Gaur, Sunanda
Ukey, Rahul
Gennaro, Maria Laura
Author_xml – sequence: 1
  givenname: Rahul
  surname: Ukey
  fullname: Ukey, Rahul
– sequence: 2
  givenname: Natalie
  surname: Bruiners
  fullname: Bruiners, Natalie
– sequence: 3
  givenname: Hridesh
  surname: Mishra
  fullname: Mishra, Hridesh
– sequence: 4
  givenname: Pankaj K.
  surname: Mishra
  fullname: Mishra, Pankaj K.
– sequence: 5
  givenname: Deborah
  surname: McCloskey
  fullname: McCloskey, Deborah
– sequence: 6
  givenname: Alberta
  surname: Onyuka
  fullname: Onyuka, Alberta
– sequence: 7
  givenname: Fei
  surname: Chen
  fullname: Chen, Fei
– sequence: 8
  givenname: Abraham
  surname: Pinter
  fullname: Pinter, Abraham
– sequence: 9
  givenname: Daniela
  surname: Weiskopf
  fullname: Weiskopf, Daniela
– sequence: 10
  givenname: Alessandro
  surname: Sette
  fullname: Sette, Alessandro
– sequence: 11
  givenname: Jason
  surname: Roy
  fullname: Roy, Jason
– sequence: 12
  givenname: Sunanda
  surname: Gaur
  fullname: Gaur, Sunanda
– sequence: 13
  givenname: Maria Laura
  surname: Gennaro
  fullname: Gennaro, Maria Laura
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35073931$$D View this record in MEDLINE/PubMed
BookMark eNp9kl2L1DAUhousuB_6B7yQgiDedE3SpkluhGH8WlgUdtXbkKYnMxnaZGzSWebfm86s68wiUtKW5Hnf5Jy859mJ8w6y7CVGlxjz-l3AROC6QIRMg6b3k-wMswoXDGF6cvB_mp2HsEKIUMaqZ9lpSRErRYnPsrsPVi999P02byDeAbg8LiFfjr0fVJcr1-Yaum7s1JAPENbeBQg5dFbbCG3ebPP-5utsx6kWnN_YSbYBHf2Qb5TW1iVeLZR1Iea3s5vbYu5_FuR59tSoLsCL--9F9uPTx-_zL8X1t89X89l1oamoYqFEbZqGMiSoMCVrieJat5zohgkwVGvEFAZGU40YEsS1EiYtkgpzwRtaXmRXe9_Wq5VcD7ZXw1Z6ZeVuwg8LqYZodQcSN5Ux2lDWcFS1uuS8LU3TYkRBIy5Y8nq_91qPTQ-tBhdTsUemxyvOLuXCbyRnvKaiTAZv7w0G_2uEEGVvw9Re5cCPQZKakLpGvCQJff0IXflxcKlViSpRxXhZ47_UQqUCrDM-7asnUzmrRbplgohI1OU_qPS00FudMmVsmj8SvDkQLEF1cRl8N0abrv8YfHXYkYdW_MlXAsge0IMPYQDzgGAkpxDLfYhlCrDchViiJOKPRClsato8ndt2_5P-BqMf9Es
CitedBy_id crossref_primary_10_1007_s40121_022_00753_2
crossref_primary_10_1186_s40001_023_01456_1
crossref_primary_10_4108_eetpht_10_5571
crossref_primary_10_1007_s10875_023_01616_2
crossref_primary_10_1016_j_clinimag_2023_110046
Cites_doi 10.1371/journal.pmed.1003656
10.1101/2021.08.15.21262077
10.1126/science.abc7520
10.1056/NEJMoa2035389
10.1016/j.cell.2020.05.015
10.1016/S0140-6736(21)02183-8
10.1016/j.vaccine.2021.05.063
10.1056/NEJMoa2034201
10.1038/s41586-021-03739-1
10.1038/s41591-021-01377-8
10.1371/journal.ppat.1005760
10.1126/science.abg9175
10.1038/s41591-021-01527-y
10.1016/j.virol.2020.05.015
10.1038/nprot.2017.039
10.1056/NEJMc2025179
10.1056/NEJMoa2027906
10.1056/NEJMoa2034577
10.1016/j.chom.2021.02.003
10.1016/j.chom.2020.03.002
10.1101/2021.05.19.444825
10.1016/j.chom.2020.04.004
10.1016/j.cmi.2021.05.004
ContentType Journal Article
Copyright 2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2022
Copyright_xml – notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7U9
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12916-022-02252-0
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ - Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1741-7015
EndPage 7
ExternalDocumentID oai_doaj_org_article_1b4ffcf57b804dc388d3fbd105ec0897
PMC8786593
A693502029
35073931
10_1186_s12916_022_02252_0
Genre Journal Article
Research Support, N.I.H., Extramural
Correspondence
Letter to the Editor
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation_xml – fundername: NIH HHS
  grantid: 75N9301900065
– fundername: NIAID NIH HHS
  grantid: R01 AI158911
– fundername: NHLBI NIH HHS
  grantid: R01 HL149450-S1
– fundername: NIH HHS
  grantid: R61 HD105619
– fundername: NIH HHS
  grantid: R01 AI158911
– fundername: NHLBI NIH HHS
  grantid: R01 HL149450
– fundername: NCATS NIH HHS
  grantid: UL1 TR003017
– fundername: ;
  grantid: R01 HL149450; R01 HL149450-S1
– fundername: ;
  grantid: 75N9301900065; 75N9301900065; R61 HD105619; R01 AI158911
GroupedDBID ---
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
MK0
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7QL
7U9
7XB
8FK
AZQEC
C1K
COVID
DWQXO
H94
K9.
M7N
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c594t-a96fbb570959f37d2a8ccd82cb79ef5cc07a1e750151e0958ca9fcb7241898b53
IEDL.DBID M48
ISSN 1741-7015
IngestDate Wed Aug 27 01:30:36 EDT 2025
Thu Aug 21 18:07:12 EDT 2025
Fri Jul 11 08:49:11 EDT 2025
Sat Jul 26 02:17:22 EDT 2025
Tue Jun 17 21:30:34 EDT 2025
Tue Jun 10 20:29:33 EDT 2025
Thu May 22 21:23:29 EDT 2025
Mon Jul 21 05:50:03 EDT 2025
Thu Apr 24 23:02:28 EDT 2025
Tue Jul 01 02:51:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords BNT162b2
Neutralizing antibodies
Ad26.COV2.S
mRNA-1273
Antigen-specific B cells
Antibody binding
Antigen-specific T cells
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c594t-a96fbb570959f37d2a8ccd82cb79ef5cc07a1e750151e0958ca9fcb7241898b53
Notes SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12916-022-02252-0
PMID 35073931
PQID 2630478361
PQPubID 42775
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_1b4ffcf57b804dc388d3fbd105ec0897
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8786593
proquest_miscellaneous_2622660832
proquest_journals_2630478361
gale_infotracmisc_A693502029
gale_infotracacademiconefile_A693502029
gale_healthsolutions_A693502029
pubmed_primary_35073931
crossref_primary_10_1186_s12916_022_02252_0
crossref_citationtrail_10_1186_s12916_022_02252_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-01-25
PublicationDateYYYYMMDD 2022-01-25
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-25
  day: 25
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC medicine
PublicationTitleAlternate BMC Med
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References LR Baden (2252_CR3) 2021; 384
KA Earle (2252_CR25) 2021; 39
F Tea (2252_CR18) 2021; 18
CS Lindestam Arlehamn (2252_CR19) 2016; 12
DA Collier (2252_CR20) 2021; 596
J Sadoff (2252_CR4) 2021; 384
DS Khoury (2252_CR24) 2021; 27
X Xie (2252_CR9) 2020; 27
AR Demonbreun (2252_CR23) 2021; 2021
2252_CR1
R Arrigucci (2252_CR11) 2017; 12
A Choi (2252_CR22) 2021; 27
L Stamatatos (2252_CR16) 2021; 372
EE Walsh (2252_CR5) 2020; 383
T Tada (2252_CR6) 2021; 2021
A Grifoni (2252_CR12) 2020; 27
J Sadoff (2252_CR27) 2021; 2021
H Chemaitelly (2252_CR28) 2021; 2021
SY Tartof (2252_CR29) 2021; 398
J Favresse (2252_CR21) 2021; 27
A Grifoni (2252_CR13) 2020; 181
FP Polack (2252_CR2) 2020; 383
AJ Greaney (2252_CR15) 2021; 29
P Datta (2252_CR7) 2021; 2021
JB Case (2252_CR10) 2020; 548
FJ Ibarrondo (2252_CR17) 2020; 383
TF Rogers (2252_CR8) 2020; 369
2252_CR26
PK Mishra (2252_CR14) 2021; 2021
34580675 - medRxiv. 2021 Sep 21:2021.09.17.21263528. doi: 10.1101/2021.09.17.21263528
References_xml – volume: 2021
  start-page: 07
  issue: 21260266
  year: 2021
  ident: 2252_CR7
  publication-title: medRxiv
– volume: 2021
  start-page: 07
  issue: 452771
  year: 2021
  ident: 2252_CR6
  publication-title: bioRxiv
– volume: 18
  issue: 7
  year: 2021
  ident: 2252_CR18
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.1003656
– ident: 2252_CR1
  doi: 10.1101/2021.08.15.21262077
– volume: 369
  start-page: 956
  issue: 6506
  year: 2020
  ident: 2252_CR8
  publication-title: Science.
  doi: 10.1126/science.abc7520
– volume: 2021
  start-page: 08
  issue: 21262569
  year: 2021
  ident: 2252_CR27
  publication-title: medRxiv
– volume: 384
  start-page: 403
  issue: 5
  year: 2021
  ident: 2252_CR3
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa2035389
– volume: 181
  start-page: 1489
  issue: 7
  year: 2020
  ident: 2252_CR13
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.015
– volume: 2021
  start-page: 11
  issue: 21266555
  year: 2021
  ident: 2252_CR23
  publication-title: medRxiv
– volume: 398
  start-page: 1407
  issue: 10309
  year: 2021
  ident: 2252_CR29
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(21)02183-8
– volume: 39
  start-page: 4423
  issue: 32
  year: 2021
  ident: 2252_CR25
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2021.05.063
– volume: 384
  start-page: 1824
  issue: 19
  year: 2021
  ident: 2252_CR4
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa2034201
– volume: 596
  start-page: 417
  issue: 7872
  year: 2021
  ident: 2252_CR20
  publication-title: Nature.
  doi: 10.1038/s41586-021-03739-1
– volume: 27
  start-page: 1205
  issue: 7
  year: 2021
  ident: 2252_CR24
  publication-title: Nat Med.
  doi: 10.1038/s41591-021-01377-8
– volume: 12
  start-page: e1005760
  issue: 7
  year: 2016
  ident: 2252_CR19
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1005760
– volume: 372
  start-page: 1413
  issue: 6549
  year: 2021
  ident: 2252_CR16
  publication-title: Science.
  doi: 10.1126/science.abg9175
– volume: 27
  start-page: 2025
  issue: 11
  year: 2021
  ident: 2252_CR22
  publication-title: Nat Med.
  doi: 10.1038/s41591-021-01527-y
– volume: 548
  start-page: 39
  year: 2020
  ident: 2252_CR10
  publication-title: Virology.
  doi: 10.1016/j.virol.2020.05.015
– volume: 2021
  start-page: 08
  issue: 21262584
  year: 2021
  ident: 2252_CR28
  publication-title: medRxiv
– volume: 12
  start-page: 1245
  issue: 6
  year: 2017
  ident: 2252_CR11
  publication-title: Nat Protoc.
  doi: 10.1038/nprot.2017.039
– volume: 383
  start-page: 1085
  issue: 11
  year: 2020
  ident: 2252_CR17
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMc2025179
– volume: 383
  start-page: 2439
  issue: 25
  year: 2020
  ident: 2252_CR5
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa2027906
– volume: 383
  start-page: 2603
  issue: 27
  year: 2020
  ident: 2252_CR2
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa2034577
– volume: 29
  start-page: 463
  issue: 3
  year: 2021
  ident: 2252_CR15
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.02.003
– volume: 27
  start-page: 671
  issue: 4
  year: 2020
  ident: 2252_CR12
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.03.002
– ident: 2252_CR26
  doi: 10.1101/2021.05.19.444825
– volume: 2021
  start-page: 04
  issue: 21255153
  year: 2021
  ident: 2252_CR14
  publication-title: medRxiv
– volume: 27
  start-page: 841
  issue: 5
  year: 2020
  ident: 2252_CR9
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.04.004
– volume: 27
  start-page: e5
  issue: 9
  year: 2021
  ident: 2252_CR21
  publication-title: Clin Microbiol Infect
  doi: 10.1016/j.cmi.2021.05.004
– reference: 34580675 - medRxiv. 2021 Sep 21:2021.09.17.21263528. doi: 10.1101/2021.09.17.21263528
SSID ssj0025774
Score 2.367986
Snippet Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving...
Background Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly...
Abstract Background Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 32
SubjectTerms Ad26.COV2.S
Ad26COVS1
Analysis
Antibodies
Antibodies, Viral
Antibody binding
Antigen-antibody reactions
Antigen-specific B cells
Antigens
BNT162b2
Cell culture
Correspondence
COVID-19
COVID-19 Vaccines
Durability
FDA approval
Hospital care
Humans
Immunity, Humoral
Immunization
Immunogenicity
Immunology
Infections
Laboratories
Lymphocytes
Lymphocytes T
mRNA
mRNA Vaccines
mRNA-1273
Neutralizing antibodies
Pandemics
Peptides
Plasma
Prevention
Proteins
Public health
Regression analysis
RNA, Messenger - genetics
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Software
Testing
Vaccination
Vaccines
Viral diseases
Viral infections
SummonAdditionalLinks – databaseName: DOAJ - Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k1KASMhcUBREztO7ONSqCqk9tBS1JvlJ11pN0Hd3aL-e2acbLQRElw4bA7rmexmHp7PzsyYkPescMp5XuY2cpNXDR7kDrg8bwrhOAtlMBY39E_P6pPL6uuVuNo56gtzwvr2wL3gDktbxeiiaKwsKu-4lJ5H6wEWBFdIlerIIeZtF1PDUksAqtmWyMj6cAVRrcRkW4YfAddJGErd-v-ck3eC0jRhcicCHT8iDwfoSGf9X35M7oX2Cbl_Orwcf0p-fZ5jQVW3vKND9hUFdEevN0uswqem9RS36THvlN70qbFhRcMC2AF2UntHl-dns0RnYDbqMP13QW_Ttj69NQ5_ZUXNDzMHSEkvZucX-VH3PWfPyOXxl29HJ_lwrkLuhKrWuVF1tFY0uAUYeeOZkc55yZxtVIjCuaIxZQAoAWggAJF0RkUYhGAvlbSCPyd7bdeGl4SG2gKLUzEoXpnCG8lLL1TwlfQx8DIj5VbM2g1Nx_Hsi4VOiw9Z6141GtSik2p0kZGPI8_PvuXGX6k_ofZGSmyXnb4AI9KDEel_GVFG3qLudV97Ojq9ntWKCwDUTGXkQ6JAt4cHcGaoXgAxYAOtCeXBhBLc1U2Ht_alh-lipVmNbz8lr0Fg78Zh5MQUuDZ0G6QBpFwDYmYZedGb4_jQcG_sbAjczcRQJ1KZjrTz69RMXDayForv_w8xviIPWPKxMmfigOytbzbhNWC2tX2T3PM3drM-fw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSAgJISivQAEjIXFAUZM4TuwTWgpVhdQeWor2ZvnZrtRNyj6K-u-ZSbxpI6QekkM8zsMzHn8Zz4OQT0VmpXUsT01gOi1rLOQOuDytM25Z4XOvDRr0D4-qg9Py55RPo8FtGd0qNzqxU9SutWgj3y0q3CASrMq_Xv5JsWoU7q7GEhr3yQNMXYZSXU9vfrg4YJtNoIyodpewtuXoclvgweE8Woy6nP3_a-ZbS9PYbfLWOrT_lDyJAJJOeo4_I_d8s00eHsYt8m3yuDfE0T6-6Dn5-32GYVbt_JpGnywKmI-er-cYm0914yga79EblS56h1m_pB5ugWCUmms6Pz6adHQadFSLTsEX9Koz9tMrbfGpS6rP9AyAJj2ZHJ-ke-3vtHhBTvd__No7SGO1hdRyWa5SLatgDK_RMBhY7QotrHWisKaWPnBrs1rnHgAGYAQPRMJqGaARIICQwnD2kmw1beNfE-orA12sDF6yUmdOC5Y7Lr0rhQue5QnJN8OubExFjhUxLlT3SyIq1bNKAZtUxyqVJeTL0OeyT8RxJ_U35OZAiUm0uwvt4kzFOalyU4ZgA6-NyEpnmRCOBeMAcXqbCVkn5APKguojUgdVoCaVZBxgdiET8rmjQGUAH2B1jGmAYcC0WiPKnRElTGI7bt7Im4pKZKluRD4hH4dm7ImOcY1v10gD-LkCHF0k5FUvnsNHw70x3yH0rkeCOxqVcUszO-9SjItaVFyyN3e_1lvyqOhmU54WfIdsrRZr_w4w2sq87ybiP7XXOg4
  priority: 102
  providerName: ProQuest
Title Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2
URI https://www.ncbi.nlm.nih.gov/pubmed/35073931
https://www.proquest.com/docview/2630478361
https://www.proquest.com/docview/2622660832
https://pubmed.ncbi.nlm.nih.gov/PMC8786593
https://doaj.org/article/1b4ffcf57b804dc388d3fbd105ec0897
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf2ISFeEN8rjGIkJB5QIInj2H5AqB2bJqRWqKOo4iWyHWer1CbQj0H_e-7cNFrEhHhIHuJzWp_vfL-cz3eEvI5Dq2zOosAUTAeJwELugMsDEXLLYhc5bdChPxim5-Pk84RP9siu3FHNwOWtn3ZYT2q8mL37_XPzERT-g1d4mb5fgs2KMJQ2xovDfZ8cgmUSWNFgkDS7CiCdPiszgHD8MxHfHaK59R0tQ-Xz-f-9at8wW-2Qyhs26uw-uVeDS9rbSsMDsufKh-TOoN4-f0R-fZrikatqvqF1fBYF_Eev1nM8p091mVN05GNkKl1sg2fdkroZdAdgSs2GzkfDnqfTsF5VGCA8o9fe8U-vtcVfWVJ9qacAOulFb3QRnFTfgvgxGZ-dfj05D-rKC4HlKlkFWqWFMVygk7BgIo-1tDaXsTVCuYJbGwodOQAbgBccEEmrVQGNwHSppOHsCTkoq9IdEepSA12sKpxiiQ5zLVmUc-XyROaFY1GHRDs2Z7ZOS47VMWaZ_zyRabadmgymJfNTk4Ud8rbp82OblOOf1H2cvYYSE2r7B9XiMqv1M4tMUhS24MLIMMktkzJnhckBfTobSiU65CXOfbY9ndosC1kvVYwD5I5Vh7zxFCiqMACr6_MNwAZMsdWiPG5RgkLbdvNOvrKdPmRxivujkqXAsFdNM_bEILnSVWukASydAqaOO-TpVhybQcO7Mfch9BYtQW1xpd1STq98unEpZMoVe_bf43tO7sZekaIg5sfkYLVYuxcA3VamS_bFRHTJYf90-GXU9Q6QrtdRuI_63_8AAm1CsQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgESQlBegUKNBOKAoiZ2HvYBoaWlaml3D32gvbm247QrdZOyj1b7p_iNzOSxbYTUWw_ZQzxONp7xzGd7HoR8YoGVNuOhb3Ku_SjFQu6Ay_00iC1nLnTa4IZ-f5DsnkS_hvFwhfxtY2HQrbLViZWizkqLe-SbLMEDIsGT8PvlHx-rRuHpaltCoxaLfbe4hiXb9NveNvD3M2M7P4-3dv2mqoBvYxnNfC2T3Jg4xQ2wnKcZ08LaTDBrUuny2Nog1aEDQwq20AGRsFrm0AimTkhhsEoEqPwHYHgDXOylw5sFXgxYqg3MEcnmFGxpiC6-DK8YfjvGr6oR8L8luGUKu26at-zezjPytAGstFdL2HOy4oo18rDfHMmvkSf1xh-t45lekOvtEYZ1leMFbXzAKGBMej4fYy4AqouM4mEBer_SSe2g66bUwSMQ_FKzoOPDQa-i06ATS3RCvqBX1eECvdIW3zql-kyPANjSo97hkb9V_vbZS3JyL3x4RVaLsnBvCHWJgS5W5k7ySAeZFjzMYumySGS546FHwnbYlW1Sn2MFjgtVLYFEompWKWCTqlilAo98Xfa5rBN_3En9A7m5pMSk3dWNcnKmGh2gQhPluc3j1IggyiwXIuO5yQDhOhsImXpkA2VB1RGwS9WjeonkMcB6Jj3ypaJA5QMfYHUTQwHDgGm8OpTrHUpQGrbb3MqbapTWVN1MMY98XDZjT3TEK1w5RxrA6wngduaR17V4Lj8ano35FaF32hHczqh0W4rReZXSXKQiiSV_e_ff2iCPdo_7B-pgb7D_jjxm1cwKfRavk9XZZO7eAz6cmQ_VpKTk9L61wD-n13dJ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dichotomy+between+the+humoral+and+cellular+responses+elicited+by+mRNA+and+adenoviral+vector+vaccines+against+SARS-CoV-2&rft.jtitle=BMC+medicine&rft.au=Ukey%2C+Rahul&rft.au=Bruiners%2C+Natalie&rft.au=Mishra%2C+Hridesh&rft.au=Mishra%2C+Pankaj+K&rft.date=2022-01-25&rft.pub=BioMed+Central+Ltd&rft.issn=1741-7015&rft.eissn=1741-7015&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12916-022-02252-0&rft.externalDocID=A693502029
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon